|dc.identifier.citation||Puaschitz NG, Strand E, Norekval TM, Dierkes J, Dahl L, Svingen GFT, et al. Dietary intake of saturated fat is not associated with risk of coronary events or mortality in patients with established coronary artery disease. J Nutr. 2015;145(2):299-305.
2. Hata J, Kiyohara Y. Epidemiology of stroke and coronary artery disease in Asia. Circ J. 2013;77(8):1923-32.
3. Onat A, Karakoyun S, Akbas T, Karadeniz FO, Karadeniz Y, Cakir H, et al. [Turkish Adult Risk Factor survey 2014: Overall mortality and coronary disease incidence in Turkey's geographic regions]. Turk Kardiyol Dern Ars. 2015;43(4):326-32.
4. Forstermann U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010;459(6):923-39.
5. Shimokawa H, Tsutsui M. Nitric oxide synthases in the pathogenesis of cardiovascular disease: lessons from genetically modified mice. Pflugers Arch. 2010;459(6):959-67.
6. Toda N, Tanabe S, Nakanishi S. Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances. Int J Angiol. 2011;20(3):121-34.
7. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol. 2003;26(10):458-64.
8. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen Risk and Cardiovascular Health Study). Clin Chem. 2007;53(2):273-83.
9. Mokhtari Z, Hosseini S, Miri R, Baghestani AR, Zahedirad M, Rismanchi M, et al. Relationship between Dietary Approaches to Stop Hypertension score and Alternative Healthy Eating Index score with plasma asymmetrical dimethylarginine levels in patients referring for coronary angiography. J Hum Nutr Diet. 2015;28(4):350-6.
10. Puchau B, Zulet MA, Urtiaga G, Navarro-Blasco I, Martinez JA. Asymmetric dimethylarginine association with antioxidants intake in healthy young adults: a role as an indicator of metabolic syndrome features. Metabolism. 2009;58(10):1483-8.
11. Watarai R, Suzuki K, Ichino N, Osakabe K, Sugimoto K, Yamada H, et al. Association between serum levels of carotenoids and serum asymmetric dimethylarginine levels in japanese subjects. J Epidemiol. 2014;24(3):250-7.
12. Barton M. Prevention and endothelial therapy of coronary artery disease. Curr Opin Pharmacol. 2013;13(2):226-41.
13. Cademartiri F, Casolo G, Midiri M. Clinical applications of cardiac CT: Springer Science & Business Media; 2012.
14. Beltrame JF DR, Tavella R. Epidemiology of Coronary Artery Disease. 2012:1-12.
15. Hosseinpoor AR, Harper S, Lee JH, Lynch J, Mathers C, Abou-Zahr C. International shortfall inequality in life expectancy in women and in men, 1950-2010. Bull World Health Organ. 2012;90(8):588-94.
16. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104(22):2746-53.
17. Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004;148(1):7-15.
18. Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Innerarity TL, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417(6890):750-4.
19. Krantz DS, McCeney MK. Effects of psychological and social factors on organic disease: a critical assessment of research on coronary heart disease. Annu Rev Psychol. 2002;53:341-69.
20. Gutierrez E, Flammer AJ, Lerman LO, Elizaga J, Lerman A, Fernandez-Aviles F. Endothelial dysfunction over the course of coronary artery disease. Eur Heart J. 2013;34(41):3175-81.
21. Poirier P, Giles TD, Bray GA, Hong YL, Stern JS, Pi-Sunyer FX, et al. Obesity and cardiovascular disease - Pathophysiology, evaluation, and effect of weight loss. Arterioscl Throm Vas. 2006;26(5):968-76.
22. Shivkar RR, Abhang SA. Ratio of serum asymmetric dimethyl arginine (ADMA)/ nitric oxide in coronary artery disease patients. J Clin Diagn Res. 2014;8(8):CC04-6.
23. Munzel T, Gori T, Bruno RM, Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741-8.
24. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation. 2005;111(3):363-8.
25. Hasdai D, Gibbons RJ, Holmes DR, Higano ST, Lerman A. Coronary endothelial dysfunction in humans is associated with myocardial perfusion defects. Circulation. 1997;96(10):3390-5.
26. Reriani MK, Lerman LO, Lerman A. Endothelial function as a functional expression of cardiovascular risk factors. Biomark Med. 2010;4(3):351-60.
27. World Health Organization. World health statistics 2016 monitoring health for the sustainable development goals, Geneva: World Health Organization;2016.
28. Roger. Heart Disease and Stroke Statistics-2011 Update: A Report From the American Heart Association. Circulation. 2011;124(16):E426-E.
29. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-44.
30. Sathiyakumar V, Blumenthal RS, Nasir K, Martin SS. Addressing knowledge gaps in the 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a review of recent coronary artery calcium literature. Curr Atheroscler Rep. 2017;19(2):7.
31. Recarti C, Unger T. Prevention of coronary artery disease: recent advances in the management of hypertension. Curr Atheroscler Rep. 2013;15(3):311.
32. Mendis S, Puska P, Norrving B. Global Atlas on cardiovascular disease prevention and control, Geneva: World Health Organization, World Heart Federation, World Stroke Organization;2011.
33. Atlanta GA, The health consequences of smoking-50 years of progress a report of the surgeon general, Rockville: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention;2014.
34. Filion KB, Luepker RV. Cigarette smoking and cardiovascular disease: lessons from framingham. Glob Heart. 2013;8(1):35-41.
35. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol. 2004;43(10):1731-7.
36. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ. 2004;328(7455):1519.
37. Price JF, Mowbray PI, Lee AJ, Rumley A, Lowe GDO, Fowkes FGR. Relationship between smoking and cardiovascular risk factors in the development of peripheral arterial disease and coronary artery disease - Edinburgh Artery Study. Eur Heart J. 1999;20(5):344-53.
38. Lucas DL, Brown RA, Wassef M, Giles TD. Alcohol and the cardiovascular system: research challenges and opportunities. J Am Coll Cardiol. 2005;45(12):1916-24.
39. Gonzalez-Alcaide G, Castello-Cogollos L, Castellano-Gomez M, Agullo-Calatayud V, Aleixandre-Benavent R, Alvarez FJ, et al. Scientific publications and research groups on alcohol consumption and related problems worldwide: authorship analysis of papers indexed in pubmed and scopus databases (2005 to 2009). Alcohol Clin Exp Res. 2013;37:E381-E93.
40. Fuchs FD, Chambless LE. Is the cardioprotective effect of alcohol real?. Alcohol. 2007; 41(5):399-402.
41. Lippi G, Franchini M, Favaloro EJ, Targher G. Moderate red wine consumption and cardiovascular disease risk: beyond the "French Paradox''. Semin Thromb Hemost. 2010;36(1):59-70.
42. Dai J, Mukamal KJ, Krasnow RE, Swan GE, Reed T. Higher usual alcohol consumption was associated with a lower 41-y mortality risk from coronary artery disease in men independent of genetic and common environmental factors: the prospective NHLBI Twin Study. Am J Clin Nutr. 2015;102(1):31-9.
43. Yang Y, Liu DC, Wang QM, Long QQ, Zhao S, Zhang Z, et al. Alcohol consumption and risk of coronary artery disease: A dose-response meta-analysis of prospective studies. Nutrition. 2016;32(6):637-44.
44. Wang ZJ, Zhou YJ, Galper BZ, Gao F, Yeh RW, Mauri L. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015;101(20):1631-8.
45. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet. 2006;368(9536):666-78.
46. Lovren F, Teoh H, Verma S. Obesity and atherosclerosis: mechanistic insights. Can J Cardiol. 2015;31(2):177-83.
47. Pi-Sunyer FX. The obesity epidemic: pathophysiology and consequences of obesity. Obes Res. 2002;10 Suppl 2:97S-104S.
48. Preis SR, Pencina MJ, Hwang SJ, D'Agostino RB, Savage PJ, Levy D, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham heart study. Circulation. 2009;120(3):212-U52.
49. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. Heart disease and stroke statistics-2014 update a report from the American Heart Association. Circulation. 2014;129(3):E28-E292.
50. Beckman JA, Greager MA, Libby P. Diabetes and atherosclerosis epidemiology, pathophysiology, and management. American Medical Assocation. 2002;287(5):2570-81.
51. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab. 2011;14(5):575-85.
52. Valenta I, Dilsizian V, Quercioli A, Schelbert HR, Schindler TH. The influence of insulin resistance, obesity, and diabetes mellitus on vascular tone and myocardial blood flow. Curr Cardiol Rep. 2012;14(2):217-25.
53. Deedwania PC, Volkova N. Metabolic syndrome and cardiovascular disease epidemiology pathophysiology and therapeutic considerations. Callifornia: 2004.
54. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24(4):683-9.
55. Weber T, Lang I, Zweiker R, Horn S, Wenzel RR, Watschinger B, et al. Hypertension and coronary artery disease: epidemiology, physiology, effects of treatment, and recommendations : A joint scientific statement from the Austrian Society of Cardiology and the Austrian Society of Hypertension. Wien Klin Wochenschr. 2016;128(13-14):467-79.
56. Bruning RS, Sturek M. Benefits of exercise training on coronary blood flow in coronary artery disease patients. Prog Cardiovasc Dis. 2015;57(5):443-53.
57. Casella-Filho A, Chagas AC, Maranhao RC, Trombetta IC, Cesena FH, Silva VM, et al. Effect of exercise training on plasma levels and functional properties of high-density lipoprotein cholesterol in the metabolic syndrome. Am J Cardiol. 2011;107(8):1168-72.
58. Volaklis KA, Tokmakidis SP, Halle M. Acute and chronic effects of exercise on circulating endothelial progenitor cells in healthy and diseased patients. Clin Res Cardiol. 2013;102(4):249-57.
59. De Biase C, De Rosa R, Luciano R, De Luca S, Capuano E, Trimarco B, et al. Effects of physical activity on endothelial progenitor cells(EPCs). Front Physiol. 2014;4.
60. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P, et al. Management of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Ann Intern Med. 2012;157(10):735-+.
61. Ravera A, Carubelli V, Sciatti E, Bonadei I, Gorga E, Cani D, et al. Nutrition and cardiovascular disease: finding the perfect recipe for cardiovascular health. Nutrients. 2016;8(6).
62. Das UN. Nutritional factors in the prevention and management of coronary artery disease and heart failure. Nutrition. 2015;31(2):283-91.
63. Tuso P, Stoll SR, Li WW. A plant-based diet, atherogenesis, and coronary artery disease prevention. Perm J. 2015;19(1):62-7.
64. Wei K, Diaz-Trelles R, Liu Q, Diez-Cunado M, Scimia MC, Cai W, et al. Developmental origin of age-related coronary artery disease. Cardiovasc Res. 2015;107(2):287-94.
65. Lacolley P, Regnault V, Nicoletti A, Li ZL, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Card Res. 2012;95(2):194-204.
66. Najib E, Puranik R, Duflou J, Xia Q, Bao S. Age related inflammatory characteristics of coronary artery disease. Int J Cardiol. 2012;154(1):65-70.
67. Leuzzi C, Modena MG. Coronary artery disease: clinical presentation, diagnosis and prognosis in women. Nutr Metab Cardiovasc Dis. 2010;20(6):426-35.
68. Nguyen JT, Berger AK, Duval S, Luepker RV. Gender disparity in cardiac procedures and medication use for acute myocardial infarction. American Heart Journal. 2008;155(5):862-8.
69. Nabel EG, Selker HP, Califf RM, Canto JG, Cao JJ, Desvigne-Nikkens P, et al. Women's ischemic syndrome evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002: Section 3: diagnosis and treatment of acute cardiac ischemia: gender issues. Circulation. 2004;109(6):e50-2.
70. Rosenfeld AG. State of the heart: building science to improve women's cardiovascular health. Am J Crit Care. 2006;15(6):556-66.
71. Stephen SA, Darney BG, Rosenfeld AG. Symptoms of acute coronary syndrome in women with diabetes: an integrative review of the literature. Heart Lung. 2008;37(3):179-89.
72. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, et al. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47(3 Suppl):S4-S20.
73. Hulley S, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal womens. Jama-J Am Med Assoc. 1998;280(7):605-613.
74. Murabito JM, Pencina MJ, Nam BH, D'Agostino RB, Wang TJ, Lloyd-Jones D, et al. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. Jama-J Am Med Assoc. 2005;294(24):3117-23.
75. Scheuner MT, Setodji CM, Pankow JS, Blumenthal RS, Keeler E. General Cardiovascular risk profile identifies advanced coronary artery calcium and is improved by family history the multiethnic study of atherosclerosis. Circ-Cardiovasc Gene. 2010;3(1):97-U302.
76. Nasir K, Michos ED, Rumberger JA, Braunstein JB, Post WS, Budoff MJ, et al. Coronary artery calcification and family history of premature coronary heart disease - Sibling history is more strongly associated than parental history. Circulation. 2004;110(15):2150-6.
77. Morrison KM, Dyal L, Conner W, Helden E, Newkirk L, Yusuf S, et al. Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. Atherosclerosis. 2010;208(2):501-5.
78. Lee JH, B OH, Han D, Park HE, Choi SY, Sung J, et al. Reassessing the usefulness of coronary artery calcium score among varying racial and ethnic groups by geographic locations: relevance of the Korea initiatives on coronary artery calcification registry. J Cardiovasc Ultrasound. 2015;23(4):195-203.
79. Lewey J, Choudhry NK. The current state of ethnic and racial disparities in cardiovascular care: lessons from the past and opportunities for the future. current cardiology reports. 2014;16(10).
80. Meadows TA, Bhatt DL, Cannon CP, Gersh BJ, Rother J, Goto S, et al. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry. Mayo Clin Proc. 2011;86(10):960-7.
81. Goldenberg NA, Bernard TJ, Hillhouse J, Armstrong-Wells J, Galinkin J, Knapp-Clevenger R, et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica. 2013;98(5):802-7.
82. Motta M, Bennati E, Cardillo E, Ferlito L, Passamonte M, Malaguarnera M. The significance of apolipoprotein-B (Apo-B) in the elderly as a predictive factor of cardio-cerebrovascular complications. Arch Gerontol Geriat. 2009;49(1):162-4.
83. Sniderman AD, Furberg CD, Keech A. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment . Lancet. 2003;362(9):408-22.
84. Malaguarnera M, Vacante M, Russo C, Malaguarnera G, Antic T, Malaguarnera L, et al. Lipoprotein(a) in cardiovascular diseases. Biomed Res Int. 2013;2013:650989.
85. Knuiman MW, Watts GF, Divtini ML. Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. Ann Epidemiol. 2004;14(9):627-32.
86. Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, Stefanadis C. Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev. 2011;25(6):239-45.
87. Lominadze D, Dean WL, Tyagi SC, Roberts AM. Mechanisms of fibrinogen-induced microvascular dysfunction during cardiovascular disease. Acta Physiol (Oxf). 2010;198(1):1-13.
88. Coffey M, Crowder GK, Cheek DJ. Reducing coronary artery disease by decreasing homocysteine levels. Crit Care Nurse. 2003;23(1):25-30.
89. Gauthier GM, Keevil JG, McBride PE. The association of homocysteine and coronary artery disease. Clinical Cardiology. 2003;26(12):563-8.
90. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339(8793):572-5.
91. Landim MB, Casella Filho A, Chagas AC. Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis. Clinics (Sao Paulo). 2009;64(5):471-8.
92. Tain YL, Hsu CN. Toxic Dimethylarginines: Asymmetric Dimethylarginine (ADMA) and Symmetric Dimethylarginine (SDMA). Toxins (Basel). 2017;9(3).
93. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscl Throm Vas. 2003;23(8):1455-9.
94. Pope AJ, Karuppiah K, Cardounel AJ. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res. 2009;60(6):461-5.
95. Teerlink T, Luo Z, Palm F, Wilcox CS. Cellular ADMA: regulation and action. Pharmacol Res. 2009;60(6):448-60.
96. Alpoim PN, Sousa LP, Mota AP, Rios DR, Dusse LM. Asymmetric Dimethylarginine (ADMA) in cardiovascular and renal disease. Clin Chim Acta. 2015;440:36-9.
97. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, et al. Symmetrical dimethylarginine: A new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006;17(4):1128-34.
98. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842-7.
99. Holven KB, Haugstad TS, Holm T, Aukrust P, Ose L, Nenseter MS. Folic acid treatment reduces elevated plasma levels of asymmetric dimethylarginine in hyperhomocysteinaemic subjects. Br J Nutr. 2003;89(3):359-63.
100. Willeit P, Freitag DF, Laukkanen JA, Chowdhury S, Gobin R, Mayr M, et al. Asymmetric dimethylarginine and cardiovascular risk: systematic review and meta-analysis of 22 prospective studies. J Am Heart Assoc. 2015;4(6):e001833.
101. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens. 1997;15(8):901-9.
102. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2000;20(9):2039-44.
103. Tarnow L, Hovind P, Teerlink T, Stehouwer CDA, Parving HH. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care. 2004;27(3):765-9.
104. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24(6):1023-30.
105. Wang J, Sim AS, Wang XL, Salonikas C, Naidoo D, Wilcken DEL. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis. 2006;184(2):383-8.
106. Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95(8):2068-74.
107. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77(8):808-13.
108. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158(2):425-30.
109. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008;196(2):958-65.
110. Kato GJ, Wang Z, Machado RF, Blackwelder WC, Taylor JGt, Hazen SL. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol. 2009;145(4):506-13.
111. Mittermayer F, Prusa AR, Pollak A, Wolzt M. Umbilical vein plasma concentrations of asymmetrical dimethylarginine are increased in male but not female neonates delivered preterm: a pilot study. Early Hum Dev. 2006;82(7):421-4.
112. Nagasaka H, Tsukahara H, Yorifuji T, Miida T, Murayama K, Tsuruoka T, et al. Evaluation of endogenous nitric oxide synthesis in congenital urea cycle enzyme defects. Metabolism. 2009;58(3):278-82.
113. Isik DU, Bas AY, Demirel N, Kavurt S, Aydemir O, Kavurt AV, et al. Increased asymmetric dimethylarginine levels in severe transient tachypnea of the newborn. J Perinatol. 2016;36(6):459-62.
114. Zhang PY. Role of omega-3 fatty acids in cardiovascular disease. Cell Biochem Biophys. 2015;72(3):869-75.
115. Keys A, Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjevic BD, et al. Epidemiological studies related to coronary heart disease: characteristics of men aged 40-59 in seven countries. Acta Med Scand Suppl. 1966;460:1-392.
116. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279-90.
117. Lichtenstein AH. Nutrient supplements and cardiovascular disease: a heartbreaking story. J Lipid Res. 2009;50 Suppl:S429-33.
118. Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU et al. Effects of lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis- a pilot study. Am J Nephrol. 2007;27(3)70-74.
119. Goralczyk T, Tisonczyk J, Fijorek K, Undas A. High tea and vegetable consumption is associated with low ADMA generation in older healthy subjects. Metabolism. 2012;61(8):1171-6.
120. Hagiwara H, Nishiyama Y, Katayama Y. Effects of eicosapentaenoic acid on asymmetric dimethylarginine in patients in the chronic phase of cerebral infarction: a preliminary study. J Stroke Cerebrovasc Dis. 2011;20(5):474-8.
121. Raimondi L, Lodovici M, Visioli F, Sartiani L, Cioni L, Alfarano C, et al. n-3 polyunsaturated fatty acids supplementation decreases asymmetric dimethyl arginine and arachidonate accumulation in aging spontaneously hypertensive rats. Eur J Nutr. 2005;44(6):327-33.
122. Erbas H, Turksever A, Aydogdu N, Cakir E. Asymmetric dimethylarginine in experimental breast cancer; action of Vitamin C and E. J Pak Med Assoc. 2015;65(8):829-33.
123. O'Doherty MG, Gilchrist SECM, Young IS, McKinley MC, Yarnell JWG, Gey KF, et al. Effect of supplementation with B vitamins and antioxidants on levels of asymmetric dimethylarginine (ADMA) and C-reactive protein (CRP): a double-blind, randomised, factorial design, placebo-controlled trial. Eur J Nutr. 2010;49(8):483-92.
124. Schmitt B, Wolters M, Kressel G, Hulsmann O, Strohle A, Kuhn-Velten WN, et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis. 2007;193(1):168-76.
125. Borgeraas H, Hertel JK, Seifert R, Berge RK, Bohov P, Ueland PM, et al. Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study. Lipids Health Dis. 2016;15:38.
126. Roszkowska R, Taranta-Janusz K, Tenderenda-Banasiuk E, Wasilewska A. The effects of breastfeeding on serum asymmetric dimethylarginine levels and body composition in children. Breastfeed Med. 2015;10(1):38-44.
127. Virdis A. Endothelial dysfunction in obesity: Role of inflammation. High Blood Press Cardiovasc Prev. 2016;23(2):83-5.
128. McLaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven GM, et al. Plasma asymmetric dimethylarginine concentrations are elevated in obese insulin-resistant women and fall with weight loss. J Clin Endocrinol Metab. 2006;91(5):1896-900.
129. Rudofsky G, Roeder E, Merle T, Hildebrand M, Nawroth PP, Wolfrum C. Weight loss improves endothelial function independently of ADMA reduction in severe obesity. Horm Metab Res. 2011;43(5):343-8.
130. Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight loss reduces circulating asymmetrical dimethylarginine concentrations in morbidly obese women. J Clin Endocrinol Metab. 2004;89(12):6277-81.
131. Pekcan G. Beslenme durumunun saptanması. Diyet El Kitabı Hatipoğlu Yayınevi Ankara. 2008:67-141.
132. Human energy requirements report of a joint FAO/WHO/UNU expert consultation, Rome: Food and Agriculture Organization;2001.
133. Merdol TK. Standart Yemek Tarifeleri. Ankara: Hatipoğlu Yayınevi; 2008.
134. Rakıcıoğlu N AN, Ayaz A, Pekcan G. Yemek ve Besin Fotoğraf Kataloğu-Ölçü ve Miktarlar. Ankara: Ata Ofset Matbaacılık; 2009.
135. Guenther PM, Reedy J, Krebs-Smith SM. Development of the Healthy Eating Index-2005. J Am Diet Assoc. 2008;108(11):1896-901.
136. Hayran M, Hayran M. Sağlık Araştırmaları İçin Temel İstatistik. Ankara: Omega Araştırma;2011.
137. Verdoia M, Schaffer A, Barbieri L, Di Giovine G, Marino P, Suryapranata H, et al. Impact of gender difference on vitamin D status and its relationship with the extent of coronary artery disease. Nutr Metab Cardiovasc Dis. 2015;25(5):464-70.
138. Nygard O, Strand E, Pedersen ER, Ebbing M, Svingen G, Schartum-Hansen H, et al. Dietary intake of n-3 long-chain polyunsaturated fatty acids, diabetes mellitus and risk of myocardial infarction in patients with suspected coronary artery disease. Circulation. 2012;126(21).
139. Lin GM, Li YH, Zheng NC, Lai CP, Lin CL, Wang JH, et al. Serum uric acid as an independent predictor of mortality in high-risk patients with obstructive coronary artery disease A prospective observational cohort study from the ET-CHD registry, 1997-2003. J Cardiol. 2013;61(1-2):122-7.
140. Onat A, Can G, Yüksel H, Ademoğlu E, Ünaltuna NE, Kaya A ve ark. TEKHARF 2017 Tıp Dünyasının Kronik Hastalıklara Yaklaşımına Öncülük. İstanbul:Logos Yayıncılık;2017.
141. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science. 2004;304(5675):1269-73.
142. Schaffer A, Verdoia M, Cassetti E, Marino P, Suryapranata H, De Luca G, et al. Relationship between homocysteine and coronary artery disease. Results from a large prospective cohort study. Thromb Res. 2014;134(2):288-93.
143. Hammal F, Ezekowitz JA, Norris CM, Wild TC, Finegan BA, Investigators A. Smoking status and survival: impact on mortality of continuing to smoke one year after the angiographic diagnosis of coronary artery disease, a prospective cohort study. BMC Cardiovasc Disord. 2014;14:133.
144. İstatistiklerle Kadın, 2016 İnternet. 2016 Erişim Tarihi 7 Mart 2017. Erişim adresi: http://www.tuik.gov.tr/PreHaberBultenleri.do?id=24643.
145. Küresel Yetişkin Tütün Araştırması Türkiye 2012, Ankara: T.C Sağlık Bakanlığı Türk Halk Sağlığı Kurumu; 2014.
146. Türkiye Beslenme ve Sağlık Araştırmaları 2010 Beslenme Durumu ve Alışkanlıklarının Değerlendirilmesi Sonuç Raporu, Ankara: Hacettepe Üniversitesi Sağlık Bilimleri Fakültesi Beslenme ve Diyetetik Bölümü; 2014.
147. Schaffer A, Verdoia M, Barbieri L, Cassetti E, Suryapranata H, De Luca G. Impact of diabetes on homocysteine levels and its relationship with coronary artery disease: A single-centre cohort study. Ann Nutr Metab. 2016;68(3):180-8.
148. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med. 1998;339(4):229-34.
149. De Luca G, Dirksen MT, Spaulding C, Kelbaek H, Schalij M, Thuesen L, et al. Impact of diabetes on long-term outcome after primary angioplasty: insights from the DESERT cooperation. Diabetes Care. 2013;36(4):1020-5.
150. Kennedy ET, Ohls J, Carlson S, Fleming K. The Healthy Eating Index: design and applications. J Am Diet Assoc. 1995;95(10):1103-8.
151. Guenther PM, Reedy J, Krebs-Smith SM. Development of the Healthy Eating Index-2005. Journal of the American Dietetic Association. 2008;108(11):1896-901.
152. Guenther PM, Casavale KO, Reedy J, Kirkpatrick SI, Hiza HA, Kuczynski KJ, et al. Update of the Healthy Eating Index: HEI-2010. J Acad Nutr Diet. 2013;113(4):569-80.
153. Xu B, Houston DK, Locher JL, Ellison KJ, Gropper S, Buys DR, et al. Higher Healthy Eating Index-2005 scores are associated with better physical performance. J Gerontol A Biol Sci Med Sci. 2012;67(1):93-9.
154. Huffman FG, De La Cera M, Vaccaro JA, Zarini GG, Exebio J, Gundupalli D, et al. Healthy Eating Index and Alternate Healthy Eating Index among Haitian Americans and African Americans with and without Type 2 Diabetes. J Nutr Metab. 2011;2011:398324.
155. Ptomey L, Goetz J, Lee J, Donnelly J, Sullivan D. Diet quality of overweight and obese adults with intellectual and developmental disabilities as measured by the Healthy Eating Index-2005. J Dev Phys Disabil. 2013;25(6):625-36.
156. Lin CTJ, Gao ZF, Lee JY. Associations between self-reported weight management methods with diet quality as measured by the Healthy Eating Index-2005. Prev Med. 2013;57(3):238-43.
157. Miller PE, Mitchell DC, Harala PL, Pettit JM, Smiciklas-Wright H, Hartman TJ. Development and evaluation of a method for calculating the Healthy Eating Index-2005 using the Nutrition Data System for Research. Public Health Nutr. 2011;14(2):306-13.
158. Hiza HA, Casavale KO, Guenther PM, Davis CA. Diet quality of Americans differs by age, sex, race/ethnicity, income, and education level. J Acad Nutr Diet. 2013;113(2):297-306.
159. Shah BS, Freeland-Graves JH, Cahill JM, Lu HX, Graves GR. Diet quality as measured by the Healthy Eating Index and the association with lipid profile in low-income women in early postpartum. J Am Diet Assoc. 2010;110(2):274-9.
160. Loke AY, Chan KN. Dietary habits of patients with coronary atherosclerosis: case-control study. J Adv Nurs. 2005;52(2):159-69.
161. Ervin RB. Healthy Eating Index-2005 total and component scores for adults aged 20 and over: National Health and Nutrition Examination Survey, 2003-2004. Natl Health Stat Report. 2011(44):1-9.
162. Da Costa Louzada ML, Chagas Durgante P, De Marchi RJ, Neves Hugo F, Balbinot Hilgert J, Pereira Padilha DM, et al. Healthy eating index in southern Brazilian older adults and its association with socioeconomic, behavioral and health characteristics. J Nutr Health Aging. 2012;16(1):3-7.
163. Kuczmarski MF, Sees AC, Hotchkiss L, Cotugna N, Evans MK, Zonderman AB. Higher Healthy Eating Index-2005 scores associated with reduced symptoms of depression in an urban population: findings from the Healthy Aging in Neighborhoods of Diversity Across the Life Span (HANDLS) Study. J Am Diet Assoc. 2010;110(3):383-9.
164. Erdem Y, Arici M, Altun B, Turgan C, Sindel S, Erbay B, et al. The relationship between hypertension and salt intake in Turkish population: SALTURK study. Blood Pressure. 2010;19(5):313-8.
165. Kielstein JT, Tsao PS. From Zanius to ADMA: ADMA - a new ''adipocytokine'' and its potential role in metabolic syndrome. J Nephrol. 2007;20(5):515-7.
166. Koc F, Tokac M, Erdem S, Kaya C, Unlu A, Karabag T, et al. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit. 2010;16(11):CR536-9.
167. Cooke JP. Does ADMA cause endothelial dysfunction?. Thromb Vasc Biol. 2000;20(1):2032-2037.
168. Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med. 2003;8(2):77-81.
169. Onat A HG, Can G, Karabulut A. Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers. Turk Kardiyol Dern Ars 2008;36(1):7-13.
170. Eid HMA, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism. 2004;53(12):1574-9.
171. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, et al. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia. 2006;49(2):351-9.
172. Kocak H, Oner-Iyidogan Y, Gurdol F, Oner P, Esin D. Serum asymmetric dimethylarginine and nitric oxide levels in obese postmenopausal women. J Clin Lab Anal. 2011;25(3):174-8.
173. Teplan V, Mahrova A, Pitha J, Racek J, Gurlich R, Teplan V, Jr., et al. Early exercise training after renal transplantation and asymmetric dimethylarginine: the effect of obesity. Kidney Blood Press Res. 2014;39(4):289-98.
174. Tanahashi K, Akazawa N, Miyaki A, Choi Y, Ra SG, Matsubara T, et al. Aerobic exercise training decreases plasma asymmetric dimethylarginine concentrations with increase in arterial compliance in postmenopausal women. Am J Hypertens. 2014;27(3):415-21.
175. Schlager O, Giurgea A, Schuhfried O, Seidinger D, Hammer A, Groger M, et al. Exercise training increases endothelial progenitor cells and decreases asymmetric dimethylarginine in peripheral arterial disease: a randomized controlled trial. Atherosclerosis. 2011;217(1):240-8.
176. Bazzano LA, Serdula MK, Liu S. Dietary intake of fruits and vegetables and risk of cardiovascular disease. Curr Atheroscler Rep. 2003;5(6):492-9.
177. Ito Y, Kurata M, Suzuki K, Hamajima N, Hishida H, Aoki K. Cardiovascular disease mortality and serum carotenoid levels: a Japanese population-based follow-up study. J Epidemiol. 2006;16(4):154-60.
178. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation. 2003;108(8):933-8.
179. Woodside JV, Yarnell JW, McMaster D, Young IS, Harmon DL, McCrum EE, et al. Effect of B-group vitamins and antioxidant vitamins on hyperhomocysteinemia: a double-blind, randomized, factorial-design, controlled trial. Am J Clin Nutr. 1998;67(5):858-66.
180. Spoelstra-de Man AME, Teerlink T, Brouwer CB, Rauwerda JA, Stehouwer CDA, Smulders YM. No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. Clin Endocrinol. 2006;64(5):495-501.
181. Ziegler S, Mittermayer F, Plank C, Minar E, Wolzt M, Schernthaner GH. Homocyst(e)ine-lowering therapy does not affect plasma asymmetrical dimethylarginine concentrations in patients with peripheral artery disease. J Clin Endocrinol Metab. 2005;90(4):2175-8.
182. Goodfellow J, Bellamy MF, Ramsey MW, Jones CJH, Lewis MJ. Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia. Journal of the American College of Cardiology. 2000;35(2):265-70.
183. Mensink RP, Zock PL, Kester AD, Katatn MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins- a meta-analysis of 60 controlled trials1. Am J Clin Nutr. 2003;77(5):1146-55.
184. Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism. 2002;51(7):843-6.
185. Kawata T, Daimon M, Hasegawa R, Teramoto K, Toyoda T, Sekine T et al. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol. 2009;132(2):286-8.
186. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004;94(2):157-61.
187. Ajtay Z, Nemeth A, Sulyok E, Cziraki A, Szabados S, Martens-Lobenhoffer J, et al. Effects of stent implementation on plasma levels of asymmetric dimethylarginine in patients with or without ST-segment elevation acute myocardial infarction. Int J Mol Med. 2010;25(4):617-24.||tr_TR